北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 胸部肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients
作者: Zhong, Jia; Li, Zheng-Xiang; Zhao, Jun; Duan, Jian-Chun; Bai, Hua; An, Tong-Tong; Yang, Xiao-Dan; Wang, Jie
关键词: Chemotherapy ; EGFR tyrosine kinase inhibitor ; non-small cell lung cancer ; polymorphism
刊名: THORACIC CANCER
发表日期: 2014-11-01
DOI: 10.1111/1759-7714.12119
卷: 5, 期:6, 页:509-516
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Respiratory System
研究领域[WOS]: Oncology ; Respiratory System
关键词[WOS]: GROWTH-FACTOR RECEPTOR ; INDUCED APOPTOSIS ; REGULATES BIM ; CHEMOTHERAPY ; MUTATIONS ; GEFITINIB ; EGFR ; IDENTIFICATION ; PACLITAXEL ; ERLOTINIB
英文摘要:

BackgroundDrug resistance significantly weakens the efficacy of cancer treatment, and the BIM (also known as the BCL2L11 gene) deletion polymorphism has been identified as a potential biomarker for drug resistance. In this retrospective study, we included a total of 290 patients with advanced non-small cell lung cancer (NSCLC) who received treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy.

MethodsThe BIM deletion polymorphism of each patient was detected by polymerase chain reaction. EGFR mutations were detected by denaturing high-performance liquid chromatography methods and the amplification refractory mutation system.

ResultsThe BIM deletion polymorphism was detected in 45/290 (15.5%) Chinese NSCLC patients. No associations were observed between the BIM deletion and clinic-pathologic characteristics of patients. The BIM deletion polymorphism was predictive of shorter progression-free survival in Chinese patients with EGFR-mutant adenocarcinoma and who were treated with EGFR-TKIs (7.30 vs. 9.53 months, P = 0.034). Additionally, we found that the BIM deletion polymorphism was an effective predictor of short progression-free survival in individuals with EGFR-mutant NSCLC and treated with chemotherapy containing pemetrexed (3.32 vs. 5.30, P = 0.012) or second-/beyond-line chemotherapy containing taxanes (1.53 vs. 2.61 months, P = 0.025). The BIM deletion was not correlated with overall survival.

ConclusionThe BIM deletion polymorphism occurs in 15.5% of Chinese NSCLC patients, and is a biomarker for resistance to TKIs and chemotherapy. However, BIM deletion was not a decisive factor in overall survival.

语种: 英语
WOS记录号: WOS:000344321000005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/52944
Appears in Collections:北京大学临床肿瘤学院_胸部肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: Peking Univ, Dept Thorac Med Oncol, Canc Hosp & Inst, Beijing 100036, Peoples R China

Recommended Citation:
Zhong, Jia,Li, Zheng-Xiang,Zhao, Jun,et al. Analysis of BIM (BCL-2 like 11 gene) deletion polymorphism in Chinese non-small cell lung cancer patients[J]. THORACIC CANCER,2014,5(6):509-516.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhong, Jia]'s Articles
[Li, Zheng-Xiang]'s Articles
[Zhao, Jun]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhong, Jia]‘s Articles
[Li, Zheng-Xiang]‘s Articles
[Zhao, Jun]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace